First RSV shots, groundbreaking gene therapy among 2024 drugs to watch

seekingalpha01-15

Some of the pioneering medical breakthroughs in recent history, including the first RSV vaccines and a first-of-its-kind gene therapy, have made it into the 2024 edition of the Drugs to Watch report ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2403890703?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1727191344/image_1727191344.jpg","is_english":true,"pubTime":"2024-01-15 01:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2403890703","market":"us","top_or_hot":-1,"title":"First RSV shots, groundbreaking gene therapy among 2024 drugs to watch","media":"seekingalpha","content":"<div>\n<p>Some of the pioneering medical breakthroughs in recent history, including the first RSV vaccines and a first-of-its-kind gene therapy, have made it into the 2024 edition of the Drugs to Watch report ...</p>\n\n<a href=\"https://seekingalpha.com/news/4054878-first-rsv-shots-gene-editing-drug-2024-drugs-watch\">Source Link</a>\n\n</div>\n","source":"seekingalpha_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>First RSV shots, groundbreaking gene therapy among 2024 drugs to watch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFirst RSV shots, groundbreaking gene therapy among 2024 drugs to watch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-15 01:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4054878-first-rsv-shots-gene-editing-drug-2024-drugs-watch><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Some of the pioneering medical breakthroughs in recent history, including the first RSV vaccines and a first-of-its-kind gene therapy, have made it into the 2024 edition of the Drugs to Watch report ...</p>\n\n<a href=\"https://seekingalpha.com/news/4054878-first-rsv-shots-gene-editing-drug-2024-drugs-watch\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014906.USD","symbol_name":"大华全球优质成长基金Acc USD","start_time":0,"source_url":"https://seekingalpha.com/news/4054878-first-rsv-shots-gene-editing-drug-2024-drugs-watch","article_id":"2403890703","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1727191344/image_1727191344.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2403890703","pubTimestamp":1705251624,"sourceInfo":{"source_id":"seekingalpha_hot_news","name":"SeekingAlpha"},"weMediaInfo":null,"summary":"Some of the pioneering medical breakthroughs in recent history, including the first RSV vaccines and a first-of-its-kind gene therapy, have made it into the 2024 edition of the Drugs to Watch report c","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014906.USD":"大华全球优质成长基金Acc USD","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","BK4512":"苹果概念","ALPMF":"Astellas Pharma, Inc.","LU1316542783.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD","CRSP":"CRISPR Therapeutics AG","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","ALPMY":"Astellas Pharma, Inc.","RHHBF":"Roche Holding Ltd","03165":"华夏欧优股对冲","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","GILD":"吉利德科学","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","RHHBY":"罗氏控股","DSNKY":"Daiichi Sankyo Co., Ltd.","CLVT":"Clarivate Plc","LU0079474960.USD":"联博美国增长基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","VRTX":"福泰制药","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BIOVF":"Swedish Orphan Biovitrum AB","LLY":"礼来","BAYRY":"Bayer A.G.","AMD":"美国超微公司","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","BAYZF":"Bayer A.G.","CALT":"Calliditas Therapeutics AB","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","JNJ":"强生","PFE":"辉瑞","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0882574055.USD":"富达全球健康医疗A ACC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","AZN":"阿斯利康","SCD":"LMP Capital & Income Fund","GSK":"葛兰素史克","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","BMRN":"拜玛林制药","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","GSK.UK":"葛兰素史克","DSKYF":"Daiichi Sankyo Co., Ltd.","REGN":"再生元制药公司","AGEN":"艾吉纳斯公司","BLUE":"bluebird bio Inc."},"translate_title":"首次RSV注射，2024种药物中的突破性基因疗法值得关注","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":1,"VRTX":1,"SCD":1,"RHHBY":1,"RHHBF":1,"REGN":1,"PFE":1,"LLY":1,"JNJ":1,"GSK":1,"GILD":1,"DSNKY":1,"DSKYF":1,"CRSP":1,"CALT":1,"BAYRY":1,"AZN":1,"AMD":1,"ALPMY":1,"ALPMF":1,"BAYZF":1,"BIOVF":1,"BLUE":1,"CLVT":1,"BMRN":1,"03165":0.6,"GSK.UK":0.6},"content_text":"Some of the pioneering medical breakthroughs in recent history, including the first RSV vaccines and a first-of-its-kind gene therapy, have made it into the 2024 edition of the Drugs to Watch report compiled by the data analytics company Clarivate (CLVT). The report highlights 13 recently launched or upcoming drugs with game-changing potential, including those expected to achieve blockbuster status (the ability to generate $1B or more in annual sales) within five years. For its analysis, the U.K.-based firm only considered drugs launched early last year or investigational drugs undergoing Phase 2 and Phase 3 trials in the pre-registrational stage and excluded treatments launched before 2023. \"New technology platforms that are likely to achieve significant proof of concept in 2024 include CRISPR-Cas9 gene editing as well as artificial intelligence /machine learning tool applications in drug discovery, clinical development, and commercial launch,\" said Henry Levy, who leads Clarivate's Life Sciences & Healthcare segment. Regeneron's (REGN) recently launched eye disease therapy, high-dose Eylea leads the list.  The VEGF inhibitor indicated at 8 mg for retinal diseases including diabetic macular edema (DME) \"offers less-frequent administration while achieving similar efficacy and safety as the current standard of care, Eylea 2mg or Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) Lucentis,\" Clarivate (CLVT) wrote. The firm projects $1.77B in 2027 sales for Eylea HD in G7 countries from patients with wet age-related macular degeneration (AMD) alone. With its German partner, Bayer (OTCPK:BAYZF) (OTCPK:BAYRY), the U.S. drugmaker expects to recognize ~$123M in U.S. net product sales for the drug in Q4 2023. Calliditas Therapeutics' (CALT) (OTCPK:CLTEF) delayed-release corticosteroid formulation, Budesonide, fully approved last year for adults with immunoglobulin A nephropathy, is ranked second. Datopotamab deruxtecan, a cancer therapy from AstraZeneca (AZN) and Daiichi Sankyo (OTCPK:DSKYF), is placed third. After Trodelvy from Gilead (GILD), the antibody-drug conjugate is set to be the second to launch for both HR-positive/HER2-negative and triple-negative breast cancer, Clarivate (CLVT) said. This week, Japan-listed shares of Daiichi (OTCPK:DSNKY) traded higher after the company said it has filed for its U.S. approval. The treatment is also under investigation as a late-line option for non-small cell lung cancer. Roche (OTCQX:RHHBY) and Sobi's (OTCPK:BIOVF) Factor VIII replacement therapy, efanesoctocog alfa for hemophilia A, is fourth in the list on its appeal for cases where novel treatments such as gene therapies are not available. Verona Pharma's investigational therapy for chronic obstructive pulmonary disease (COPD), ensifentrine, is also among Clarivate's (CLVT) drugs to watch given its novelty. The non-steroidal therapy is currently under FDA review, with a target action date of June 26, 2024. The firm highlighted its potential against neutrophilic inflammation, a key mechanism in COPD that often responds poorly to steroids. Abrysvo and Arexvy, for which developers Pfizer (NYSE:PFE) and GSK (NYSE:GSK)/Agenus (AGEN), respectively, received U.S. approval to launch in 2023 as the first FDA-cleared vaccines for respiratory syncytial virus (RSV), also made their debut in the list. As did one-time gene therapies, Casgevy and Lyfgenia from Crispr Therapeutics (NASDAQ:CRSP)/ Vertex Pharma (NASDAQ:VRTX), and Bluebird Bio (BLUE). Both drugs are the first disease-modifying therapies for inherited blood disorders, sickle cell disease (SCD) and beta-thalassemia, Clarivate (CLVT) said. According to the firm, Casgevy, the first gene editing therapy to receive regulatory approval in November, is expected to generate $1.32B in sales in 2029. While the U.S. approved both treatments for SCD in December, Casgevy is currently under FDA review for transfusion-dependent beta-thalassemia, with a target action date of March 30. With estimated sales of $2.7B in 2029, Johnson & Johnson's (JNJ) investigational prostate cancer therapy Akeega has also made it onto the list, along with its bispecific antibody, Talvey, cleared in the U.S. last year under the FDA's accelerated pathway for multiple myeloma. Omvoh and zolbetuximab, two monoclonal antibodies developed by Eli Lilly (LLY) and Astellas Pharma's (OTCPK:ALPMF), respectively, round out the list. \"A delayed U.S. launch due to manufacturing concerns by the U.S. FDA means that it remains a drug to watch for 2024, Clarivate (CLVT) wrote about Omvoh, approved in October for ulcerative colitis. This week, Astellas (OTCPK:ALPMY) failed to win an FDA nod for zolbetuximab in gastric or gastroesophageal junction cancer due to issues at a third-party manufacturing facility. The company expects to refile for approval. Clarivate (CLVT) highlighted 14 treatments as drugs to watch in its 2023 list. Twelve of those were granted regulatory approval. Donanemab, Eli Lilly's (LLY) Alzheimer's therapy, and Roctavian, BioMarin's (BMRN) gene therapy for hemophilia A were part of that list. Donanemab did not clear regulatory hurdles last year, while Roctavian had a lackluster launch in its first few months after approval. \"These examples show just how challenging drug launches can be,\" Clarivate's (CLVT) Levy argued.  More on CRISPR, GSK, etc.  Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) Rebranded Investor Movement Index gains in December, still ‘moderately low’ Pfizer suggests shareholders reject mini-tender offer by TRC Capital Investment","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2403890703"}